Brought to you by 
Cubist, Emisphere partner in oral delivery of daptomycin
26 Apr 2021
Executive Summary
Antimicrobial drug developer Cubist Pharmaceuticals will license oral drug delivery technology from Emisphere Technologies (oral delivery of large-molecule drugs) to apply to its Phase III antibiotic Cidecin (daptomycin), currently an injectable product, and other lipopeptides.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cubist, Emisphere partner in oral delivery of daptomycin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice